Hmmm Really? (7.11.2025)
Dr. Jack Cush reviews the news and journal reports from this past week - some obvious, other new thoughts and some - hmmm, reallly?
Read Article
Rheums! Question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast.
https://t.co/HsqM9xLNtP https://t.co/voONsOLeSK
Dr. John Cush @RheumNow( View Tweet )
CMS to Test Prior Authorization Model in Traditional Medicare
Medpage Today
The Centers for Medicare & Medicaid Services (CMS) announced a new experimental model late last week to streamline some prior authorizations under the traditional Medicare program, but some politicians and experts are concerned that it could result in more delays in care.
Read Article
Is the term polymyositis obsolete?.. now being replaced by dermatomyositis, necrotizing myopathy, inclusion body myositis, antisynthetase syndrome & overlap myositis. Full read overview of inflammatory myositis & new treatments from Joint Bone & Spine https://t.co/X46sptp1Ax https://t.co/QqyMv6fkVS
Links:
Dr. John Cush @RheumNow( View Tweet )
❓️Is early intensive therapy with combination csDMARDs or TNFi superior to standard step care for the treatment of moderate to severe #psoriatic_arthritis?
🅰️ Yes
🔅Check out the SPEED RCT presented by @DrLauraCoates at #EULAR2025
OP0089
@RheumNow
#Strategy
Dr. John Cush @RheumNow( View Tweet )
ICYMI: SLE: advances to achieve deep B-cell depletion
The race is on for the first chimeric antigen receptor (CAR)-based therapy to be approved for the treatment of systemic lupus erythematosus. Its main principle is to induce deep B-cell depletion, with the hope to reset the B-cell aberrant immunity for a sustained clinical remission. At EULAR
Read Article
"Education is not the learning of facts, but the training of the mind to think." - A. Einstein
"Education is not the learning of facts, but the training of the mind to think." - Malcolm X
Education is knowing what to do when you dont know what to do https://t.co/5CF4g78OEH
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Clinical and Therapeutic Challenges in Connective Tissue Disease and ILD
Connective tissue diseases (CTDs) and interstitial lung disease (ILD) represent a challenging intersection of systemic autoimmunity and progressive respiratory impairment. Research presented at EULAR 2025 continues to highlight the importance of CTD-ILD and the evolving landscape of therapeutic
Read Article
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory https://t.co/Qy9fy3GWKm
Dr. John Cush @RheumNow( View Tweet )
Foot and ankle #OA is often underrecognized..
1 in 6 people over 50 have foot OA!
#EULAR2025 @RheumNow https://t.co/4wGSzC8dvi
Dr. John Cush @RheumNow( View Tweet )
ICYMI: AGA Guideline: Prevention and Treatment of Hepatitis B Virus Reactivation in At-Risk Individuals
The American Gastroenterology Association has published its revised clinical practice guidelines for the prevention and treatment of hepatitis B virus (HBV) reactivation in at-risk patients, particularly those with immune-mediated disease, receiving immunomodulatory therapy and steroids.
Read Article
ICYMI: EGPA in 2025
Formerly classified as an ANCA-associated vasculitis, EGPA is both most commonly ANCA negative and clinically different to the other two ANCA-associated vasculitis conditions, GPA and MPA. The management of EGPA has frequently fallen into the trap of being copied from its more common and well-
Read Article
ICYMI: Secukinumab promise in PMR is real
Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.
Read Article
How to patients with rheumatic diseases consume online health information?
78% used internet for health information
50% use it atleast a month
66% found online information superior
41% used social media!
80% using it to find treatment optio ns!
@rheumnow #EULAR2025 https://t.co/ZcjwPaqsjT
Dr. John Cush @RheumNow( View Tweet )
#EULAR2025 in numbers
💫5125 abstracts submitted from 95 countries
💫177 scientific sessions
💫350 speakers from 45 nations
💫Balanced gender split of speakers & chairpersons
💫Fresh sessions format
💫Integration of European Workshop for Rheum Research https://t.co/7WoknFuVLL
Dr. John Cush @RheumNow( View Tweet )
Glucocorticoid Tapering in SLE
Dr. Yuz Yusof discusses abstract POS1224 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/oI992YLvnB https://t.co/mPmMxcpMey
Dr. John Cush @RheumNow( View Tweet )
GLP 1 Receptor Agonists in axSpA
Dr. David Liew reviews POS1232 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/88Ms7ce7XX https://t.co/tt3qZH1hJT
Dr. John Cush @RheumNow( View Tweet )
Rituximab - Super Responders Exist in SLE
Dr. Yuz Yusof reports on abstract POS0325 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/LkYzMtsErn https://t.co/awRhQmbhoT
Dr. John Cush @RheumNow( View Tweet )
Rheumatology RoundUp: EULAR 2025
https://t.co/csWNjWyIg7 https://t.co/B6AvK1zBqX
Dr. John Cush @RheumNow( View Tweet )
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.
https://t.co/zt0OxwQ2BO https://t.co/eFqHwROQOj
Dr. John Cush @RheumNow( View Tweet )
New IL-17 Inhibition New Molecular Constructs
Dr. Philip Mease offers his perspective from the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/zz4NRITsRN https://t.co/FrUbmsjxxB
Dr. John Cush @RheumNow( View Tweet )
ICYMI: Combination treatments in Psoriatic Arthritis
Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity.
Read Article
ARD's Impact Factor
The 2024 Impact Factor for ARD is 20.6 – an increase from 20.3 in 2023. This retains the journal’s position as second of 58 titles in the rheumatology category and confirms its status as the top-ranking journal for the publication of original research in both https://t.co/dtMTejkhcc
Dr. John Cush @RheumNow( View Tweet )
SCLERODERMA Pt education page from JAMA Dermatology https://t.co/hILqCeUnE2 https://t.co/QPKLqTQfPj
Links:
Dr. John Cush @RheumNow( View Tweet )
MRI Lesions in Early axSpA vs Non-axSpA
Dr. Adela Castro reports on abstract OP0310 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/sVWpyUT1IY https://t.co/wzobROoH1K
Dr. John Cush @RheumNow( View Tweet )
Recent Blogs
